PLA2G7 and retinal disorder: All analyses for retinopathy outcomes were therefore adjusted for this factor by using a competing risk analysis, which directly estimates the effect of Lp-PLA2 activity separately on the event of interest (incidence or progression) and the competing event (death), and also allows non-informative censoring for participants when neither event occurred before the end of the study period.